Acceptance of high platelet reactivity as a risk factor: Now, what do we do about it?

JACC: Cardiovascular Interventions

Volumn 3, Issue 10, 2010, Pages 1008-1010

  Gurbel, Paul A ^a   Tantry, Udaya S ^a  

^a SINAI CENTER FOR THROMBOSIS RESEARCH   (United States)

Author keywords

clopidogrel; high platelet reactivity; loss offunction allele

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 2C19;

ACUTE CORONARY SYNDROME; DRUG EFFICACY; DRUG MEGADOSE; FOOD AND DRUG ADMINISTRATION; GENOTYPE; HUMAN; LOADING DRUG DOSE; NOTE; PERCUTANEOUS CORONARY INTERVENTION; PHARMACODYNAMICS; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION;

EID: 77958527078     PISSN: 19368798     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcin.2010.08.011     Document Type: Editorial

References (21)

1. P.A. Gurbel, K.P. Bliden, B.L. Hiatt, and C.M. O'Connor Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity Circulation 107 2003 2908 2913
2. W.C. Lau, P.A. Gurbel, and P.B. Watkins Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance Circulation 109 2004 166 171
3. J.T. Brandt, S.L. Close, and S.J. Iturria Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel J Thromb Haemost 5 2007 2429 2436
4. A.R. Shuldiner, J.R. O'Connell, and K.P. Bliden Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy JAMA 302 2009 849 857
5. P.A. Gurbel, K.P. Bliden, K.A. Zaman, J.A. Yoho, K.M. Hayes, and U.S. Tantry Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study Circulation 111 2005 1153 1159
6. L. Bonello, L. Camoin-Jau, and S. Arques Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study J Am Coll Cardiol 51 2008 1404 1411
7. P.A. Gurbel, R.C. Becker, K.G. Mann, S.R. Steinhubl, and A.D. Michelson Platelet function monitoring in patients with coronary artery disease J Am Coll Cardiol 50 2007 1822 1834
8. L. Bonello, U.S. Tantry, and R. Marcucci Consensus and future directions on the definition of high on-treatment platelet reactivity to ADP J Am Coll Cardiol 56 2010 919 933
9. C.M. Barker, S.S. Murray, and P.S. Teirstein Pilot study of the antiplatelet effect of increased clopidogrel maintenance dosing and its relationship to CYP2C19 genotype in patients with high on-treatment reactivity J Am Coll Cardiol Intv 3 2010 1001 1007
10. M.J. Price, S. Endemann, and R.R. Gollapudi Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation Eur Heart J 29 2008 992 1000
11. P.A. Gurbel, U.S. Tantry, A.R. Shuldiner, and D.J. Kereiakes Genotyping: one piece of the puzzle to personalize antiplatelet therapy J Am Coll Cardiol 56 2010 112 116
12. FDA Drug Safety Communication: reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm203888.htm Accessed August 5, 2010
13. S.B. Damani, and E.J. Topol The case for routine genotyping in dual-antiplatelet therapy J Am Coll Cardiol 56 2010 109 111
14. D.R. Holmes Jr., G.J. Dehmer, S. Kaul, D. Leifer, P.T. O'Gara, and C.M. Stein ACCF/AHA clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons J Am Coll Cardiol 56 2010 321 341
15. D. Trenk, W. Hochholzer, and M.F. Fromm Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents J Am Coll Cardiol 51 2008 1925 1934
16. Gurbel PA, Tantry US, Antonino MJ, et al. The influence of cytochrome P450 2C19 (*)2 and (*)17 genotype, diplotype and metabolizer status on platelet reactivity in patients on maintenance clopidogrel therapy. Presented at: 59th Annual Scientific Session of the American College of Cardiology; March 1416, 2010; Atlanta, GA.
17. K. Bliden, U. Tantry, and M. Antonino Differential effect of ticagrelor versus clopidogrel on the prevalence of high platelet reactivity: results from the onset-offset study Circulation 120 2009 S1172 S1173
18. M. Valgimigli, G. Campo, and N. de Cesare ; Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel (3T/2R) Investigators Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study Circulation 119 2009 3215 3222
19. Y.H. Jeong, J.Y. Hwang, and I.S. Kim Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patients with AMI (ACCEL-AMI) study Circ Cardiovasc Interv 3 2010 17 26
20. P.A. Gurbel, K.P. Bliden, and M.J. Antonino The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19 (*)2 genotype: first experience in patients J Thromb Haemost 8 2010 43 53
21. M.J. Price, P.B. Berger, and D.J. Angiolillo Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial Am Heart J 157 2009 818 824 824.e1